Spots Global Cancer Trial Database for squamous cell lung carcinoma
Every month we try and update this database with for squamous cell lung carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | NCT02186847 | Adenosquamous L... Bronchioloalveo... Large Cell Lung... Lung Adenocarci... Non-Small Cell ... Recurrent Non-S... Squamous Cell L... Stage IIIA Non-... Stage IIIB Non-... | Radiation Thera... Carboplatin Metformin Paclitaxel | 18 Years - | NRG Oncology | |
| MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | NCT01294306 | Adenosquamous L... Bronchioloalveo... Large Cell Lung... Lung Adenocarci... Recurrent Non-S... Squamous Cell L... | Akt Inhibitor M... Erlotinib Hydro... Laboratory Biom... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer | NCT04507919 | Small Cell Lung... | Dabrafenib Trametininb | 18 Years - 99 Years | Novartis | |
| Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer | NCT03199651 | Cigarette Smoke... Current Smoker Lung Adenocarci... Squamous Cell L... Stage IV Non-Sm... | Best Practice Biospecimen Col... Biospecimen Col... Laboratory Biom... Medical Chart R... Quality-of-Life... Questionnaire A... Smoking Cessati... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | NCT04460729 | Non-small Cell ... | Capmatinib | 18 Years - | Novartis | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) | NCT04741789 | Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Capmatinib | 18 Years - 99 Years | Novartis | |
| TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003) | NCT02920476 | Squamous Cell L... | TAS-102 | 18 Years - 90 Years | University of Florida | |
| Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC) | NCT04741789 | Carcinoma, Non-... Non-Small Cell ... Non-Small-Cell ... Nonsmall Cell L... | Capmatinib | 18 Years - 99 Years | Novartis | |
| A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | NCT02974725 | Non-Small Cell ... Melanoma | LXH254 LTT462 Trametinib Ribociclib | 18 Years - | Novartis | |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | NCT01646125 | Advanced Non Sm... | AUY922 Docetaxel Pemetrexed | 18 Years - | Novartis | |
| A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | NCT04460729 | Non-small Cell ... | Capmatinib | 18 Years - | Novartis | |
| An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | NCT01646125 | Advanced Non Sm... | AUY922 Docetaxel Pemetrexed | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
